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Graphical Abstract 
 
MGB-BP-3, a resilient and effective antibiotic against Gram-positive bacteria. 
Why Antibacterial Minor Groove Binders Are a Good Thing 
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Abstract: The challenge of antimicrobial resistance is well understood. Combining  
potency with resilience is unlikely to be met using the standard medicinal 
chemistry paradigm of single drug, single target, single effect. Our approach using 
specially designed minor groove binders for DNA (Strathclyde MGBs), whilst 
formally attacking a single molecular target, in practice disrupts many biological 
processes such that the emergence of resistance can be expected to be low. The 
first example of this approach to reach the clinic, MGB-BP-3, is highly effective 
against Gram positive bacteria and has been successfully completed a Phase 1 
clinical trial against Clostridium difficile infections by our development partner, 
MGB Biopharma. Mechanism of action studies with S. aureus as the target 
organism provided evidence consistent with the expectation. RNAseq experiments 
show that there are substantial changes in gene expression such that the 
bacterium faces multiple metabolic challenges to its survival. In particular 
processes associated with cell wall integrity and energy production are affected. 
Attempts to generate resistant strains have failed. Taken together, these properties 
identify Strathclyde minor groove binders as significant new compounds in the 
fight against antibacterial resistance. 
Keywords: antibacterial, minor groove binder, DNA, antimicrobial resistance, 
mechanism of action, 
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Introduction 
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MGB-BP-3 (Figure 1) is a novel antibiotic candidate derived by chemical-synthesis and SAR from Distamycin - 
a natural product antibiotic that acts by binding to the minor groove of DNA. It that has very strong 
antibacterial activity against all susceptible and multi-resistant Gram-positive pathogens tested, including 
methicillin-resistant and susceptible Staphylococcus species, pathogenic Streptococcus species, Vancomycin-
Resistant and susceptible Enterococcus and Clostridium difficile. 
The oral formulation of MGB-BP-3 has successfully completed a clinical Phase I study for the treatment of C. 
difficile infections and through our development partner, MGB Biopharma, has been granted qualified 
infectious disease product (QIPD) status by the U.S. FDA for the treatment of Clostridium difficile-associated 
Diarrhoea (CDAD).  
 
 
 
 
Figure 1. Structure of MGB-BP-3 
Resilience to the generation of resistance is very important in a new antibiotic. The discovery concept for 
MGB-BP3 and related minor groove binders from Strathclyde (S-MGBs) was to design compounds that have 
low toxicity to mammalian cells but, by targeting bacterial DNA, cause multiple disruption to bacterial 
metabolism thereby minimising the probability of the development of resistance. This study investigates the 
mode of action of MGB-BP-3 and applies RNA-sequencing transcriptomics to determine the effect of drug 
on global gene expression of Staphylococcus aureus and demonstrates high resilience to the development 
of resistance. 
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The antibacterial drug, MGB-BP-3 
The general antibacterial properties of MGB-BP-3 are introduced in the next three slides. 
MGB-BP-3 is broadly active against Gram-positive bacteria (Table 1) but is only weakly active at non-
clinically useful levels against Gram-negative bacteria. It is probable that the lack of activity against Gram-
negative bacteria is associated with the function of efflux pumps. MGB-BP-3 is fluorescent allowing its 
uptake into cells to be observed (Figure 2). Uptake is clearly different in different cell types; S. aureus  cells 
can be seen to light up but the mouse melanoma cell line, B16F0luc, does not. This provides evidence for 
the intracellular activity of MGB-BP-3 and for its selective toxicity. 
The data in Table 1 show that the MICs of MGB-BP-3 are 1 mg/L or less for many Gram-positive bacteria. 
These numbers are approximately equivalent to sub-micromolar for the test substance, the bis-
trifluoroacetate salt (MW 859.7) and allow a comparison with concentration dependence of viability of 
mammalian cell lines with the MICs (Figure 3). This comparison indicates that MGB-BP-3 has an in vitro 
safety index of up to 500 fold depending upon the cell line used.. Evidently at high concentrations 
mammalian cells are affected but this is well above the expected clinical concentration to be used. 
Questions can now be posed. 
Is the multiple target multiple effect design plan real?  Addressed by RNAseq analysis. 
What effects does binding to DNA by MGB-BP-3 have? Also addressed by RNAseq analysis. 
Are these effects consistent with a reasonable interpretation of the biology of BP3? Addressed by RNAseq 
analysis, PCR evaluation of changes in protein levels, and DNA footprinting of MGB-BP-3 itself. 
Is MGB-BP-3 resilient to the development of resistance? 
Organism 
MGB-BP-3 
n= MIC50 (mg/L) MIC90 (mg/L) MBC50 (mg/L) MBC90 (mg/L) 
Group B Streptococci 15 0.25 1 0.25 1 
Group C Streptococci 15 0.25 1 0.5 1 
Group G Streptococci 15 0.5 0.5 0.5 0.5 
Methicillin-resistant Staphylococcus aureus 15 1 2 1 2 
Methicillin-resistant Staphylococcus epidermidis 15 0.25 0.5 0.5 2 
Methicillin-susceptible Staphylococcus aureus 15 0.5 1 1 2 
Methicillin-susceptible Staphylococcus epidermidis 15 0.25 0.5 0.25 2 
Streptococcus constellatus 15 0.25 0.5 0.5 1 
Streptococcus mitis 15 0.5 2 0.5 2 
Streptococcus pyogenes 15 0.25 0.5 0.25 2 
Vancomycin-resistant Enterococcus faecalis 15 2 2 >32 >32 
Vancomycin-resistant Enterococcus faecium 15 1 2 >32 >32 
Vancomycin-susceptible Enterococcus faecalis 15 1 2 >32 >32 
Vancomycin-susceptible Enterococcus faecium 15 1 2 >32 >32 
 
Examples of species selectivity of MGB-BP3 (Table 1) 
Selective uptake of MGB-BP-3 by bacterial and mammalian cells 
S. aureus  without MGB-BP3 
Brightfield               under UV 
S. aureus  with MGB-BP3 
Brightfield         under UV 
B16FOluc cells with MGB-BP3 
Brightfield                 under UV 
Figure 2 
Figure 3. Data obtained by Carol Clements, University of Strathclyde  
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Low toxicity of MGB-BP-3 to mammalian cell lines 
MGB-BP-3 on HS27, human 
fibroblast cells 
MGB-BP-3 on L929, mouse 
fibroblast cells 
MICs cluster MICs cluster 
9 
MGB-BP-3 as a drug 
MGB-BP-3 is a lipophilic molecule that is known to undergo self-association in aqueous solution. Self 
association of MGB-BP-3 and its relatives has been studied in detail by NMR spectroscopy (Parkinson et.al. 
Med. Chem. Commun., 2013, 4, 1105-1108), which showed that a head-to-tail dimer was especially stable in 
aqueous solution; this dimer is believed to bind to DNA intact leading to exceptionally tight binding (Suckling 
et.al. J. Med. Chem. 2007, 50, 6116-6125). 
Rheological measurements show time an temperature dependent molecular aggregation. Dynamic light 
scattering of dilute solutions shows presence of two aggregate particles (radii ~ 5 nm to 100 nm). Clear 
solutions, colloidal phases, and gel phases have all been observed. The type of solution observed depends 
upon pH, composition, concentration, and temperature. Consistent with self-aggregation, the pKa of the 
morpholino tail group is unusually low (Figure 4). These properties lead to non-absorption from the GI tract 
making MGB-BP-3 ideal for treatment of Clostridium difficile infections for which it has been developed by our 
partner company, MGB Biopharma. 
 
 
  
Figure 4. Data obtained by Prof. Gavin Halbert, University of Strathclyde. B refers to MGB-BP-3. 
Results and discussion 
 
The protocol for the RNA-seq experiments was as follows: 
RNA-seq analysis was undertaken on S. aureus following challenge with 0.5 x MIC (0.1 μg/mL) MGB-BP-3. 
Triplicate samples of RNA were extracted at 10 min after challenge (Figure 5). Approximately 5 - 7.5 million 
sequencing reads were obtained per sample (average length between 100 - 170 bp) using an Ion Torrent PGM.  
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The data were analysed using CLC Genomics Workbench 7.5.1 software (Qiagen). The ‘Empirical Analysis 
of DGE’ (Differential Gene Expression) Tool was used, with Bonferroni-adjusted p-value, to trimmed reads. 
 
The biological replicates were found to group together in a PCA plot (Figure 6). 
 
RNA-Seq analysis identified 698 transcripts showing significant changes in expression profile (Figure 7). 
Key enzymes of glycolysis were enhanced whereas the pentose phosphate pathway was reduced; flux 
through the TCA cycle was likely reduced significantly as citrate synthase and isocitrate dehydrogenase 
were reduced. These changes are associated with energy depletion. In addition, biosynthesis of 
nucleotides and certain amino acids were altered but it is not yet clear if the changes are directly due to 
MGB action or an indirect effect (Figure 8). 
 
Results from RNA-seq experiment 
MGB-BP-3  
treated 
 samples 
Ctrl samples 
Figure 6.                 Figure 7. 
Genes significantly downregulated 
transcription ATP catabolic 
process 
metabolic 
process 
regulation of 
cell shape 
pathogenesis 
transmembrane 
transport 
translation 
protein folding 
regulation of 
transcription 
Figure 8. 
Target binding sites suggested 
Scrutiny of the RNAseq results suggests a number of consensus binding sites for MGB-BP-3 on genomic DNA 
from S. aureus (Figure 9). These are AT rich, consistent with the known binding preferences of MGB-BP-3 as 
determined by footprinting (Prof Keith Fox, University of Southampton Figure 10).  
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Figure 9. 
Figure 10. 
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Possible significance of target binding sites 
RNA-seq reveals differential gene expression in S. aureus  with single nucleotide resolution from which 
some promoter sequences can be identified  (Figure 11, red highlights). Interestingly, many of these contain 
target sequences for MGB-BP-3. Figure 12 shows the sequence of the polynucleotide, HexA, used as 
substrate for footprinting with 3 of the preferred binding sites for MGB-BP-3 that match the promoter 
sequences highlighted in yellow boxes. The combined evidence clearly demonstrates that MGB-BP-3 has 
multiple binding sites and can therefore be expected to have multiple effects. 
 
Figure 11. 
Figure 12. 
15 
Translation of gene effects into metabolism 
Figures 13 and 14 show metabolic maps in which the effects of MGB-BP-3 are highlighted in 
red.  
 
Figure 13, downregulated genes, shows substantial effects on nucleotide and cofactor 
metabolism (top right). Impaired input to the tricarboxylic acid cycle is also indicated together 
with downregulation of the electron transport chain; these effects would be expected to cause 
significant problems in energy production for the bacterium, which is consistent with the 
catastrophic death observed in kill curves caused by MGBs. 
 
Figure 14 shows what could be considered to be the bacterial response to the challenge of 
MGB-BP-3. Clearly it is widespread. Glycolytic enzymes are seen to be upregulated ,perhaps to 
restore energy production. A shunt across the tricarboxylic acid cycle is highlighted. Lipid 
metabolism is also enhanced, perhaps suggesting that attempts to reinforce the cell wall are 
being made. Effects are also seen in nucleotide and cofactor metabolism. 
 
Scientifically, it is important to confirm at least in some cases that the pattern emerging carries 
through to gene expression. This was done for 6 enzymes using qRT-PCR. The results (Figure 
15) confirm the interpretation of the RNA-seq data.   
 
 
Multiple effects on metabolism shown by downregulated genes 
Figure 13. 
Multiple effects on metabolism shown by upregulated genes 
Figure 14. 
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PCR confirmation of RNA-seq output 
To confirm the significance of RNA-seq data, qRT-PCR studies were undertaken with respect to 
selected genes, including both up and downregulated genes (Figure 15). It was found that the 
qRT-PCR data matches that from RNA-seq.  
Figure 15. 
RNA-seq demonstrates that the design concept and expectations with MGB-BP-3 
are supported by experimental results: there are multiple effects that contribute to 
the antibacterial action. In this context it is not possible to identify a single lethal 
event. Nevertheless, the PCR confirmation supported two genes of importance, 
namely those coding for phosphomevalonate kinase and isocitrate dehydrogenase; 
both have been identified as essential genes in S. aureus (Forsyth et al., Molecular 
Microbiology 2002, 43, 1387-1400; Christiansen et al., PLOS One  2014, 9, e89018. 
 
 
In a further experiment, when S. aureus was grown at sub-MIC80 concentrations of 
MGB-BP-3 no resistance to BP3 was observed even after passaging for more than 
200 generations. In contrast, resistance was observed to develop with rifampicin 
used under the same conditions. This is strong evidence for the resilience of MGB-
BP-3 to drug induced resistance. 
RNA-seq in the context of MGB-BP-3 as a resilient antibiotic 
Conclusions 
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• MGB-BP-3 is a new antibiotic with a wide range of biological effects on its target Gram-positive 
bacteria.  
• Treatment of S. aureus with MGB-BP-3 causes a large number of changes in gene expression 
many associated with energy production. 
• The binding sites of MGB-BP-3 to DNA in S. aureus as shown by RNA-seq experiments are 
consistent with those observed by footprinting using the HexAB sequences developed by Fox 
(Hampshire and Fox, Biochimie 2008, 90, 988-998) All binding sites are AT rich but single G or C 
bases are accommodated. 
• There is a similarity between the sequences identified by RNA-seq and footprinting with the 
recognition sites for a number of transcription factors in S. aureus. 
• Together these observations support the concept that MGB-BP-3 is a single molecule with 
multiple targets on DNA that lead to multiple biological changes in S. aureus, the combination of 
which is lethal. 
• Attempts to induce resistance in S. aureus by multiple passages of MGB-BP-3 have failed to 
generate a resistant strain. 
 
MGB-BP-3 can therefore be described by a profile that implies an intrinsic resilience and avoidance 
of future bacterial resistance, a major potential benefit in the clinic. 
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